outperform price
earn report chang price
increas confid top-line
acceler drive alpha
evrisi thesi updat continu pound consist
result highlight yet anoth guidanc rais
bear like pick weak cyno print write
import keep perspect cyno less
rev known issu acceler mdx gyn beat
provid comfort around trend sustain given
consum busi mdx standout growth
ou dd growth us point solid share gain
panther fusion yet kick us faxitron focal
acquisit grew deal annual
next month accret top-line could add
bp organ management sound confid gm trajectori
investor like overlook one-tim impact
bp look forward tweak organ growth
estim confid dd ep growth increas st
number need come fx hedg could revers
believ eurobond offer enough off-set
environ compani beat number like
come would call victori reiter
outperform rate tweak pt price-to-earnings
evercor isi grate consider vijay
kumar medic suppli devic
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
like
top-line rais guidanc strong molecular dx strength ou strength impli share gain
gyn surg perform turn around first time qs
dens breast propos fda mention increment posit given geniu superior vs
like
oper margin came st albeit management cite one-tim item point
medic aesthet miss st management cite weaker ou sale driven challeng asia
ep guidanc rais mostli tax driven despit core beat
us biz acceler lead bh molecular dx
legaci intenational grew dd ex blood cyno
mm faxitron rev breast imag focal intervent breast
continu instal consist number new system maintain premium price
dens breast mqsa increment posit
new product includ intellig clariti hd smartcurv affirm prone biopsi system continu
brevera biopsi system contribut slightli growth quarter although expect continu face suppli
constraint mt
driven strong ww sale legaci women health assay chlamydia gonorrhea hpv trichomona
well new quantit viral load test
continu expect ou grow dd us msd
ou still underdevelop term assay menu expans vs us
expect panther assay menu mid high volume molecular space get even stronger
molecular dx reflect updat price new contract
sale forc strengthen improv underli busi trend well competit posit
myo grew ldd vs hsd prior
novo declin less msd prior
domest revenu finish line management expect sale ou weak driven mainli challeng
women health product declin ldd sale skin-rel product declin
asia
gm expect improv onetim item inventori reserv medic aesthet intenational fx tariff
impact
cyno higher blood screen product mix hw well
book write-down hit cog opex
relat lower carri valu product like sculpsur monalisa touch tempsur vitalia
tweak blood screen contribut vs prior
rais fx hw vs impact ep prior due usd strengthen
lower tax rate vs prior
valuat methodolog base mix discount cash flow analysi rel valuat multipl
failur execut cyno weigh sentiment multipl higher expect declin mammographi
margin expans thesi doesnt play due higher invest turn around busi
articl articl
time dissemin may
analyst william tong alina levchuk vijay kumar primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
